Dulaglutide And Insulin MicrosecretiON in type I Diabetes - DIAMOND - DIAMOND

Hospices Civils de Lyon0 个研究点目标入组 72 人开始时间: 2018年4月4日最近更新: 2021年8月17日

研究概览

暂无简介。

•Adult patients with T1D> 4years, with age range 20-60years
•- Diabetes onset after the age of 15years
•- Duration of diabetes <15 years
•- Treated with continuous sub-cutaneous insulin infusions (CSI) or multiple daily injections of insulin (MDI)
•- Measuring their blood sugar at least four times daily
•- Glycated hemoglobin (HbA1C) at screening >7.5 and <9.5%
•- BMI<30.0kg/m2
•- Patients who gave its written informed consent to participate to the study
•- Patients affiliated to a social insurance regime
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 72
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Patients with type 2 diabetes (T2D)
•-Subjects with history of severe hypoglycemia or recent history of diabetic ketoacidosis
•-History of gastrointestinal disease with prolonged nausea or vomiting, liver or kidney diseases, pancreatitis, thyroid medullary cancer or familial history of multiple endocrine neoplasia type 2
•-Estimated glomerular filtration rate<60ml/min/ 1.73m2 (CKD-EPI method)
•-Any uncontrolled disease
•-Chronic use of drugs that directly affect GI mobility
•-Chronic use of paracetamol containing products, which may falsely raise sensor glucose readings

发起方